Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

Clara Montagut, Alba Dalmases, Beatríz Bellosillo, +16

Nature Medicine

Extracellular DomainMedicineColorectal CancerCancer GenomicsCetuximab Resistance +5

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients

Joana Vidal, Laura Muinelo, Alba Dalmases, +18

Annals of Oncology

Emergence of Multiple <i>EGFR</i> Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

Sabrina Arena, Beatríz Bellosillo, Giulia Siravegna, +22

Clinical Cancer Research

Inhibition of the Canonical IKK/NF&amp;kappa;B Pathway Sensitizes Human Cancer Cells to Doxorubicin

M. Tapia, Irene González-Navarrete, Alba Dalmases, +12

Cell Cycle

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Francisco Javier Sánchez-Martín, Beatríz Bellosillo, Mariona Gelabert‐Baldrich, +19

Clinical Cancer Research

Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin

Federico Rojo, Irene González-Navarrete, Rafael Bragado, +16

Clinical Cancer Research

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma

Álvaro Taus, Laura Camacho, Pedro Rocha, +11

Clinical Lung Cancer

Egfr Mutation LoadOncologyTumor HeterogeneityMedicineEgfr-mutant Lung Adenocarcinoma +9

HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer

Aïda Sampera, Francisco Javier Sánchez-Martín, Oriol Arpí, +13

Molecular Cancer Therapeutics

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer

Alba Dalmases, Irene González, Sílvia Menéndez, +13

Oncotarget

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer

Jetzabel García-Parra, Alba Dalmases, Beatriz Morancho, +15

European Journal of Cancer

Tumor BiologyBreast OncologyMedicineBreast CancerCancer Biology +8